Eltrombopag Added to Standard Immunosuppressive Treatment as Front‐Line Therapy for Severe Aplastic Anemia: Long‐Term Outcomes of the Phase‐3 Randomized Superiority EBMT ‐ SAAWP RACE Study
American Journal of Hematology · 2026
DOI: 10.1002/ajh.70445 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift American Journal of Hematology, 2026. Verfasst von Antonio M Risitano und 52 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Study Unit, EBMT, Leiden, the Netherlands. Hauptthemen laut MEDLINE: Benzoates, Anemia, Aplastic, Hydrazines, Pyrazoles. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Novartis Pharmaceuticals Corporation, Pfizer, Alexion Pharmaceuticals.
Abstract (Originalsprache)
The RACE study (NCT02009747) compared horse antithymocyte globulin (hATG) plus cyclosporine A (CsA) ± eltrombopag as initial immunosuppressive treatment (IST) for severe aplastic anemia. Here we report the final 2‐year analysis of this prospective randomized phase III study. One hundred ninety‐seven treatment‐naive patients were randomized to standard IST (hATG 40 mg/kg × 4 days and CsA 5 mg/kg/day; arm A; n = 101) or standard IST + eltrombopag at the dose of 150 mg/day (arm B; n = 96) from day +14 until 6 months (or 3 months, in case of complete response). The median follow‐up was 23.2 months. The 2‐year cumulative incidence of complete response was significantly superior in arm B (62.4% vs. 35.3%; p < 0.001). The 2‐year overall survival (OS) was 86% in arm A and 91% in arm B ( p = 0.081), with hazard ratio (HR), adjusted for age and disease severity, of 0.54 ( p = 0.064). The 2‐year disease‐free survival (DFS) was 56% vs. 37% (adjusted HR = 0.49; p < 0.001), while event‐free survival (EFS) was 48% vs. 32% ( p < 0.001), with adjusted HR = 0.54 ( p < 0.001), both significantly superior for arm B. The cumulative incidence of relapse was comparable in the two arms, while evolution to clinical paroxysmal nocturnal hemoglobinuria was 8% in arm A and 1% in arm B ( p = 0.041). The risk of clonal evolution remained negligible, with one patient in arm A and two in arm B developing karyotypic abnormalities. The initial hematological response benefit of eltrombopag added to IST as front‐line treatment of AA is associated with better 2‐year OS, DFS, and EFS without increased risk of secondary myeloid malignancies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Clinical Study Unit, EBMT, Leiden, the Netherlands.
- Department of Clinical Medicine and Surgery, Federico II University, Naples, Italy.
- Hematology and Hematopoietic Transplant Unit, AORN S. Giuseppe Moscati, Avellino, Italy.
- Department of Public Health and Infectious Diseases, University of Rome Sapienza, Rome, Italy.
- Haematological Medicine, King's College Hospital NHS Foundation Trust, London, UK.
- Leiden Study Unit, EBMT, Leiden, the Netherlands.
ORCID-Profile: Antonio M Risitano, Simona Iacobelli, Austin Kulasekararaj, Brian Piepenbroek, Morag Griffin, Constantijn J M Halkes, Christian Recher, Edouard Forcade, Juan Carlos Vallejo, Roochi Trikha, Shreyans Gandhi, Anna Maria Raiola, L G M Daenen, Etienne Daguindau, Erfan Nur, Wilma Barcellini, Nigel H Russell, Louis Terriou, Anna Paola Iori, Anna Sureda, Isabel Sánchez-Ortega, Blanca Xicoy, Flore Sicre de Fontbrune, Talha Munir, Jennifer M L Tjon, Florence Rabian, Luana Marano, Anita Hill, Elena Palmisani, Petra Muus, Marica Laurino, Jakob R Passweg, Gérard Socié, Ghulam J Mufti, Carlo Dufour, Régis Peffault de Latour
Förderung
- Novartis Pharmaceuticals Corporation
- Pfizer
- Alexion Pharmaceuticals
- Bloodwise UK
- Cancer Research UK
Zitieren
APA
Risitano, A. M., Iacobelli, S., Kulasekararaj, A., van Os, M., Terwel, S. R., Tuffnell, J., Piepenbroek, B., Griffin, M., Halkes, C. J. M., Recher, C., Barraco, F., Forcade, E., Vallejo, J. C., Drexler, B., Mear, J. B., Trikha, R., Gandhi, S., Raiola, A. M., Daenen, L. G. M., …, & Severe Aplastic Anaemia Working Party of the EBMT (2026). Eltrombopag Added to Standard Immunosuppressive Treatment as Front‐Line Therapy for Severe Aplastic Anemia: Long‐Term Outcomes of the Phase‐3 Randomized Superiority EBMT ‐ SAAWP RACE Study. American Journal of Hematology. https://doi.org/10.1002/ajh.70445
Vancouver
Risitano AM, Iacobelli S, Kulasekararaj A, van Os M, Terwel SR, Tuffnell J, et al. Eltrombopag Added to Standard Immunosuppressive Treatment as Front‐Line Therapy for Severe Aplastic Anemia: Long‐Term Outcomes of the Phase‐3 Randomized Superiority EBMT ‐ SAAWP RACE Study. American Journal of Hematology. 2026. doi:10.1002/ajh.70445
BibTeX
@article{Risitano2026,
author = {Risitano, Antonio M and Iacobelli, Simona and Kulasekararaj, Austin and van Os, Marleen and Terwel, Sofie R and Tuffnell, Joe and Piepenbroek, Brian and Griffin, Morag and Halkes, Constantijn J M and Recher, Christian and Barraco, Fiorenza and Forcade, Edouard and Vallejo, Juan Carlos and Drexler, Beatrice and Mear, Jean-Baptiste and Trikha, Roochi and Gandhi, Shreyans and Raiola, Anna Maria and Daenen, L G M and de Groot, Marco R and Daguindau, Etienne and Nur, Erfan and Barcellini, Wilma and Russell, Nigel H and Terriou, Louis and Paola Iori, Anna and Barberi, Walter and Sureda, Anna and Sánchez-Ortega, Isabel and Xicoy, Blanca and Jarque, Isidro and Cavenagh, James and de Fontbrune, Flore Sicre and Frieri, Camilla and Munir, Talha and Tjon, Jennifer M L and Tavitian, Suzanne and Praire, Aline and Clement, Laurence and Rabian, Florence and Marano, Luana and Hill, Anita and Palmisani, Elena and Muus, Petra and Marotta, Serena and Cacace, Fabiana and Laurino, Marica and Passweg, Jakob R and Socié, Gérard and Mufti, Ghulam J and Dufour, Carlo and Peffault de Latour, Régis and Severe Aplastic Anaemia Working Party of the EBMT, Severe Aplastic Anaemia Working Party of the EBMT},
title = {Eltrombopag Added to Standard Immunosuppressive Treatment as Front‐Line Therapy for Severe Aplastic Anemia: Long‐Term Outcomes of the Phase‐3 Randomized Superiority EBMT ‐ SAAWP RACE Study},
journal = {American Journal of Hematology},
year = {2026},
doi = {10.1002/ajh.70445}
}
EUVIMED